Physician profile
Anna Afonso
NPI 1386008225
$167.88
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $17.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.44 | 2021 | |
| Pfizer INC. | $19.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.75 | 2021 | |
| Gilead Sciences, INC. | $17.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.21 | 2021 | |
| Currax Pharmaceuticals LLC | $14.97 | 2021 | |
| Abbvie INC. | $14.70 | 2021 | |
| Genentech USA, INC. | $14.49 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Afonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.